/** blogpostTitle: Laxmi Dental Q1FY27: Record revenue, better mix, and a bigger US push blogpostSlug: laxmidental-q1fy27 blogpostCoverImageUrl: null blogpostCoverImageDescription: An ultra realistic corporate finance scene showing a clean desktop dashboard on a large monitor with three rising line charts representing quarterly revenue, EBITDA margin, and PAT margin. A second panel shows a stacked bar chart splitting revenue into laboratory domestic, laboratory international, aligner solutions, and a small scanner sales segment. The numbers and labels are not readable, but the shapes clearly show record quarterly revenue, higher gross margin, and reduced scanner contribution. The setting is a modern boardroom with neutral lighting, subtle dental model props on the side table, and no company logos or text. blogpostShortTitle: Laxmi Dental Q1FY27 record quarter */

Laxmi Dental Q1FY27: Record revenue, better mix, and a bigger US push

Laxmi Dental Limited began FY27 with its highest-ever quarterly revenue. In Q1FY27, consolidated revenue from operations stood at INR 74.7 crore, up 13.9% year on year. Profitability also improved on a better product mix, with gross margin rising to 78.6% and EBITDA margin improving to 19.2%.

The quarter’s message was not just about growth but about the type of growth. The dental laboratory business and the aligner solutions business were the key drivers. Scanner sales were low in the quarter, which supported the gross margin profile. Profit after tax after share of profit or loss from JVs came in at INR 10.3 crore, up 23.8% year on year, with PAT margin at 13.8%.

What drove the record quarter

Management described Q1FY27 as a broad-based quarter led by dental laboratories and aligners. Dental laboratory revenue excluding scanners grew 23.5% year on year. Within that, international operations recorded particularly strong growth of 37.4% year on year, reflecting the company’s relationships and market presence across global markets.

Aligner Solutions also maintained momentum. Revenue grew 28.6% year on year, with both Bizdent and Vedia contributing. Bizdent revenue increased 27.8% year on year, while Vedia grew 29.3% year on year.

Scanner sales were a swing factor, and in Q1FY27 their contribution was minimal. Management explained on the concall that scanners are essentially a trading item, typically carrying a 15% to 20% margin, and can create lumpiness in gross margins depending on mix. In Q1FY27, scanner revenue was INR 2.2 crore compared with INR 5.9 crore in Q1FY26.

Financial snapshot (Q1FY27)

Segment mix: labs and aligners did the heavy lifting

The company’s revenue mix in Q1FY27 underlined a clear point: core dental offerings were strong, and scanner sales were not the primary contributor.

Laboratory offerings including scanners totalled INR 50.0 crore in Q1FY27, while Aligner Solutions totalled INR 23.6 crore. Scanner sales were INR 2.2 crore for the quarter.

Kids-e-Dental, which the company describes as a paediatric dental business (a jointly controlled entity), recorded revenue of INR 6.8 crore in Q1FY27. The presentation clarifies that revenue from Kids-e-Dental is not included in revenue from operations under Ind AS because it is jointly controlled.

Operating levers: leadership, footprint, and digital workflow

Beyond the numbers, the quarter included several execution-oriented updates.

First, the company has strengthened leadership in the US. Management said it appointed a new CEO to head the USA business, based in the US, with over 32 years of experience in medical devices and the dental industry. The stated intent is to build a more market-focused strategy and sustain growth in a key international market.

Second, the company expanded its support footprint in India. Management stated it established three new support facilities across multiple cities to deepen regional presence, enhance market penetration, and improve service for existing dental partners.

Third, digital workflow continues to be a central theme. The presentation highlighted increasing intraoral scanner adoption and higher digital penetration in lab units. For FY26, the company reported digital units penetration of 75.5% in domestic lab and 75.2% in international lab. On the concall, management said current domestic digital penetration is in the 75% to 80% range.

Management also discussed scanner economics and deployment. It stated an average selling price of about INR 3 lakh per scanner. For FY27, it indicated a plan to deploy about 800 to 1,000 scanners, while continuously evaluating the roadmap based on technology and demand.

Costs, investments, and what to watch

The quarter showed margin improvement but also some cost signals worth tracking.

Employee costs increased sequentially, primarily due to the appointment of the new CEO for the USA business and additions across sales and other key areas.

Other expenses rose year on year, driven by higher freight costs, ECL provisions, and spending towards AI-led automation initiatives. Management described these AI initiatives as important for efficient scalability. On the concall, it said it is doing AI crowns in beta models and expects initial costs to be higher, with better cost efficiency as scale improves.

The company also shared facility-related plans. It executed a letter of intent to acquire land in Palghar, Maharashtra, with the aim of transitioning from currently leased premises to an owned facility. Management said it currently pays close to INR 2 crore per year as rent for two domestic properties and expects that an owned, unified facility could improve workflow efficiency, provide better cost control, and support future scalability. Management also said it expects the transition to be phased and non-disruptive, aided by digital workflows.

Separately, management stated that in FY27 it plans to invest in adding new machinery to modernize and expand the manufacturing capacity of Kids-e-Dental, with an aim to support long-term growth and enhance operational efficiencies.

Closing takeaways

Q1FY27 was a strong operational quarter for Laxmi Dental with record revenue, improving margins, and healthy growth across laboratories and aligners. The quarter also reinforced the company’s strategic priorities: deeper penetration of its dental network, stronger leadership presence in the US, expansion of support infrastructure in India, and continued investment in automation and digital workflows.

The key variables to monitor from here are the mix impact from scanner sales, the pace of domestic laboratory acceleration that management expects over the coming quarters, and the execution of facility consolidation plans following the Palghar land letter of intent. If the company sustains growth in core dental offerings while keeping cost inflation controlled, the improved profitability profile in Q1FY27 offers a benchmark for the rest of FY27.